Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new research that helps define clinically meaningful improvement in overall health reported by people living with tardive dyskinesia who ...
Everyday Health on MSN
7 daily habits to help you manage tardive dyskinesia
Alongside medical treatment, adopting healthy habits can help you manage tardive dyskinesia. Find out what experts recommend.
An oral drug designed to treat the core symptoms of autism spectrum disorder, has been dubbed by some as 'the Ozempic of ...
Neurocrine's expanding drug portfolio could drive substantial growth through 2031.
Tardive Dyskinesia (TD) doesn’t just change the way the body moves. It also changes the way we view that body, in mirrors, in ...
Mentara Therapeutics, a new neuropsychiatry company backed by SPRIM Global Investments, today launched with the acquisition of EM-221, ...
Major Parkinson’s breakthrough as new pill offers hope of treating symptoms and has fewer side-effects - Trial found patients on solengepras had 37 minutes less ‘off’ time each day when dopamine drugs ...
The Brighterside of News on MSN
FDA approves once-daily Parkinson’s pill (Juvmo) built on decades of work by husband-and-wife team
Once-daily tavapadon offers a new Parkinson’s treatment option, with symptom benefits supported by trials and important ...
Mentara Therapeutics has launched as a new neuropsychiatry company backed by SPRIM Global Investments and acquired MTA-304, a Phase 2-ready PDE10A inhibitor, from EuMentis Therapeutics. The compound ...
Dr. Ning Xu of Tsinghua University lost his Nikon microscopy prize when researchers found AI-generated artifacts in his cilia ...
ALPHA | Overview of Technology◾️What is Neurocrine Biosciences' SciTech?Pharmaceutical technology targeting neurotransmission ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results